SAP Advanced Therapy Orchestration (SAP ATO)

Solutions for Advanced Therapy Management

Cell & gene therapies started a new area of patient centric treatments. The need to guarantee that the right patient gets the right treatment in the right time and quality raises the bar for the supply of advanced therapies. At Tenthpin, we understand the effort required for an end-to-end supply chain, considering the diverse supply possibilities.

Let's talk

How do cell & gene therapies impact biopharma operations?

Personalized treatments require a whole new end-to-end capability along the biopharma supply chain.

Cell & gene therapies (CGTs) are a major innovation in drug development, offering new ways to address severe conditions such as cancer and rare genetic disorders. These advanced therapies aim to treat, prevent, or potentially cure illnesses by targeting their root causes. Beyond drug development, CGTs will drive significant changes across biopharma operations and the patient-centric value network. Today there are many advanced therapies like:

Cell therapies — Autologous (patient-specific) and allogeneic (donor-based)

Gene therapies — Viral vector delivery, in vivo and ex vivo approaches

Radioligand therapies — Targeted radiopharmaceuticals combining a targeting molecule with a radioactive payload

Combination products — Medical devices integrated with biologics

Plasma-derived biologics — Derived from donated blood plasma through fractionation

Orchestrating batch-to-one processes

Individualized therapies create highly complex supply chain and manufacturing processes, which are not always compatible with traditional pharmaceutical processes. The personalized treatments generate a need to establish batch-to-one processes and guarantee that the right patient gets the proper treatment at the right time and quality. The complexity is driven by non-traditional scenarios, like autologous, allogeneic, clinic, or enhanced traditional processes.

Learn more

Personalized treatments require complex supply chain and manufacturing processes

graphics_cell_gene_treatment_management_ 1

-- Non-traditional scenarios like autologous, allogeneic, clinic or enhanced traditional processes are driving the complexity.

Designing advanced therapy management systems

Orchestrating end-to-end processes from order placement through to patient delivery.

Today, there are no standard processes and solutions available when it comes to cell therapies. Getting the architecture right is key. We are investing in SAP S/4HANA as a core to our integrated solution for personalized medicine, as we see great potential in SAP S/4HANA and the built-in functionalities in SAP R/3 or SAP ECC.

tenthpin_lifeSciencesinnovation_final_no bg

Pioneering an SAP-based solution for commercial operations

Tenthpin partnered with a Top 5 pharma company to rapidly design, develop, and deploy an SAP-based cell & gene therapy treatment management solution. This was SAP Cell & Gene Therapy Orchestration (SAP CGTO).
Covering the end-to-end process from order placement through patient delivery, SAP CGTO was deployed for the commercial operations of one of the world’s first approved cell & gene therapies.
SAP CGTO has now expanded and changed to SAP Advanced Therapy Orchestration (ATO).

Designing and deploying a cloud-based industry standard

SAP Advanced Therapy Orchestration (ATO), an industry standard that enables leading capabilities for biopharma companies, covers the following:

Traceability and transparency (COI & COC)

External supplier (CMO) engagement

Supply chain visualization

Shipping and logistics management

Electronic labeling (eLabeling)

Why is Tenthpin in the lead?

As one of the leading consulting firms for Life Sciences, Tenthpin understands the effort required for an end-to-end supply chain. We have partnered with key leaders in the industry to design, develop, and deploy an SAP-based cell & gene and advanced therapy treatment management solutions.

Learn more

Modern solutions meet patient-specific needs

In clinical trials and commercial operations, cell & gene therapies require interactions, dependencies, and orchestration capabilities with external supply chain partners. At Tenthpin, we understand this ecosystem. Our consultants all have the unique Tenthpin DNA: combining tech-savvy with a deep understanding of the intricacies of the Life Sciences industry.